Research programme: cystic fibrosis gene therapies - Pfizer/University of Iowa
Latest Information Update: 28 Mar 2020
At a glance
- Originator Pfizer; University of Iowa Research Foundation
- Class Gene therapies
- Mechanism of Action Gene transference; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in Cystic-fibrosis in USA (Parenteral)
- 04 Feb 2016 Early research in Cystic fibrosis in USA (Parenteral)
- 04 Feb 2016 University of Iowa research Foundation and Pfizer finalised a licensing agreement for the development of gene therapies in USA for Cystic fibrosis